Global X Genomics & Biotechnology ETF Price & Performance (GNOM)

Several ETFs experienced liquidations recently, including Global X Nasdaq 100 ESG Covered Call ETF and Global X S&P 500 ESG Covered Call ETF. Investors received payouts ranging from $25.62 to $29.63 per share. These movements reflect a broader trend of fund closures in niche sectors.12

BeiGene, Ltd. is expanding its immunology portfolio through collaborations and clinical trials. Key developments include a Phase 1 trial for TYK2 inhibitor BGB-23339 and partnerships for innovative treatments like ociperlimab. The company aims to strengthen its position in immune-related therapies.34

The Global X Genomics & Biotechnology ETF saw a 7.8% decline recently, driven by outflows and underperforming holdings like Moderna. Despite its challenges, the ETF remains a key player in the biotech sector, offering exposure to genomic research and biotechnology companies.56